Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 3/20 | 0.52 |
| ▸ | HSD17B7 | P56937 | 2/20 | 0.52 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7072009 | 0.89 | HSD17B7 (0.54) | SRD5A1HSD17B7SRD5A2 | |
| SCHEMBL9066656 | 0.86 | HSD17B7 (0.57) | SRD5A1HSD17B7SRD5A2 | |
| SCHEMBL9066658 | 0.86 | HSD17B7 (0.57) | SRD5A1HSD17B7SRD5A2 | |
| SCHEMBL13656754 | 0.83 | HSD17B7 (0.59) | SRD5A1HSD17B7SRD5A2 | |
| SCHEMBL4264792 | 0.83 | HSD17B7 (0.59) | SRD5A1HSD17B7SRD5A2 | |
| SCHEMBL4264788 | 0.83 | HSD17B7 (0.59) | SRD5A1HSD17B7SRD5A2 | |
| SCHEMBL8724745 | 0.80 | SRD5A1 (0.57) | SRD5A1SRD5A2 | |
| SCHEMBL9066061 | 0.80 | HSD17B7 (0.55) | SRD5A1HSD17B7SRD5A2 | |
| SCHEMBL9270145 | 0.80 | HSD17B7 (0.55) | SRD5A1HSD17B7SRD5A2 | |
| SCHEMBL9066057 | 0.80 | HSD17B7 (0.55) | SRD5A1HSD17B7SRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040082556-A1 | Inhibitors of type 5 and type 3 17beta-hydroxysteroid dehydrogenase and methods for their use | ENDORECHERCHE, INC. | 2004-04-29 | — | — | US | disclosed |
| EP-1321146-A2 | Inhibitors of type 5 and 3 17beta-hydroxysteroid dehydrogenase and methods for their use | Endorecherche Inc. (CA) | 2003-06-25 | — | — | EP | disclosed |
| US-6541463-B1 | 17-spirolactone derivatives of steroids | ENDORECHERCHE, INC. (CA) | 2003-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082556-A1 | Inhibitors of type 5 and type 3 17beta-hydroxysteroid dehydrogenase and methods for their use | HSD17B11, HSD17B3, HSD17B1 | SRD5A1 5/4885HSD17B7 15/4885SRD5A2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.